Actively Recruiting
L-carnitine Supplementation in Rheumatoid Arthritis Patients
Led by German University in Cairo · Updated on 2025-01-07
60
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.
CONDITIONS
Official Title
L-carnitine Supplementation in Rheumatoid Arthritis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years old
- Diagnosis of rheumatoid arthritis according to 2010 ACR/EULAR criteria for at least 6 months
- Currently treated with one or more conventional DMARDs for 6 months or more with stable dose for 1 month before study start
- Active rheumatoid arthritis with DAS28 ESR score of 3.2 or higher
- Patient or legal representative has signed informed consent
You will not qualify if you...
- Pregnant or lactating females
- Liver dysfunction with ALT or AST greater than 1.5 times the upper normal limit
- Kidney dysfunction with serum creatinine over 1.2 mg/dl
- Any active infection or concurrent cancer
- Uncontrolled medical conditions or other rheumatic diseases
- Taking drugs that may interact with carnitine, such as warfarin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Demerdash hospital
Cairo, Demerdash, Egypt
Actively Recruiting
Research Team
M
Mariam Ehab, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here